IBDEI17D ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,19541,2)
;;=^5007396
;;^UTILITY(U,$J,358.3,19542,0)
;;=I69.821^^67^877^26
;;^UTILITY(U,$J,358.3,19542,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19542,1,3,0)
;;=3^Dysphasia following other cerebrovascular disease
;;^UTILITY(U,$J,358.3,19542,1,4,0)
;;=4^I69.821
;;^UTILITY(U,$J,358.3,19542,2)
;;=^5007523
;;^UTILITY(U,$J,358.3,19543,0)
;;=I69.221^^67^877^25
;;^UTILITY(U,$J,358.3,19543,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19543,1,3,0)
;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
;;^UTILITY(U,$J,358.3,19543,1,4,0)
;;=4^I69.221
;;^UTILITY(U,$J,358.3,19543,2)
;;=^5007460
;;^UTILITY(U,$J,358.3,19544,0)
;;=I69.392^^67^877^29
;;^UTILITY(U,$J,358.3,19544,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19544,1,3,0)
;;=3^Facial weakness following cerebral infarction
;;^UTILITY(U,$J,358.3,19544,1,4,0)
;;=4^I69.392
;;^UTILITY(U,$J,358.3,19544,2)
;;=^5007517
;;^UTILITY(U,$J,358.3,19545,0)
;;=I69.192^^67^877^30
;;^UTILITY(U,$J,358.3,19545,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19545,1,3,0)
;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
;;^UTILITY(U,$J,358.3,19545,1,4,0)
;;=4^I69.192
;;^UTILITY(U,$J,358.3,19545,2)
;;=^5007454
;;^UTILITY(U,$J,358.3,19546,0)
;;=I69.292^^67^877^32
;;^UTILITY(U,$J,358.3,19546,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19546,1,3,0)
;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
;;^UTILITY(U,$J,358.3,19546,1,4,0)
;;=4^I69.292
;;^UTILITY(U,$J,358.3,19546,2)
;;=^5007486
;;^UTILITY(U,$J,358.3,19547,0)
;;=I69.092^^67^877^31
;;^UTILITY(U,$J,358.3,19547,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19547,1,3,0)
;;=3^Facial weakness following ntrm subarachnoid hemorrhage
;;^UTILITY(U,$J,358.3,19547,1,4,0)
;;=4^I69.092
;;^UTILITY(U,$J,358.3,19547,2)
;;=^5007422
;;^UTILITY(U,$J,358.3,19548,0)
;;=I69.892^^67^877^33
;;^UTILITY(U,$J,358.3,19548,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19548,1,3,0)
;;=3^Facial weakness following other cerebrovascular disease
;;^UTILITY(U,$J,358.3,19548,1,4,0)
;;=4^I69.892
;;^UTILITY(U,$J,358.3,19548,2)
;;=^5007548
;;^UTILITY(U,$J,358.3,19549,0)
;;=I69.351^^67^877^36
;;^UTILITY(U,$J,358.3,19549,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19549,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff right dominant side
;;^UTILITY(U,$J,358.3,19549,1,4,0)
;;=4^I69.351
;;^UTILITY(U,$J,358.3,19549,2)
;;=^5007504
;;^UTILITY(U,$J,358.3,19550,0)
;;=I69.352^^67^877^35
;;^UTILITY(U,$J,358.3,19550,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19550,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff left dominant side
;;^UTILITY(U,$J,358.3,19550,1,4,0)
;;=4^I69.352
;;^UTILITY(U,$J,358.3,19550,2)
;;=^5007505
;;^UTILITY(U,$J,358.3,19551,0)
;;=I69.353^^67^877^37
;;^UTILITY(U,$J,358.3,19551,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19551,1,3,0)
;;=3^Hemiplga fol cerebral infrc aff right nondom side
;;^UTILITY(U,$J,358.3,19551,1,4,0)
;;=4^I69.353
;;^UTILITY(U,$J,358.3,19551,2)
;;=^5007506
;;^UTILITY(U,$J,358.3,19552,0)
;;=I69.354^^67^877^38
;;^UTILITY(U,$J,358.3,19552,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,19552,1,3,0)
;;=3^Hemiplga fol cerebral infrc affecting left nondom side
;;^UTILITY(U,$J,358.3,19552,1,4,0)
;;=4^I69.354
;;^UTILITY(U,$J,358.3,19552,2)
;;=^5007507
;;^UTILITY(U,$J,358.3,19553,0)
;;=I69.151^^67^877^41
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI17D 3749 printed Apr 09, 2024@21:58:01 Page 2
IBDEI17D ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,19541,2)
+2 ;;=^5007396
+3 ;;^UTILITY(U,$J,358.3,19542,0)
+4 ;;=I69.821^^67^877^26
+5 ;;^UTILITY(U,$J,358.3,19542,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,19542,1,3,0)
+8 ;;=3^Dysphasia following other cerebrovascular disease
+9 ;;^UTILITY(U,$J,358.3,19542,1,4,0)
+10 ;;=4^I69.821
+11 ;;^UTILITY(U,$J,358.3,19542,2)
+12 ;;=^5007523
+13 ;;^UTILITY(U,$J,358.3,19543,0)
+14 ;;=I69.221^^67^877^25
+15 ;;^UTILITY(U,$J,358.3,19543,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,19543,1,3,0)
+18 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
+19 ;;^UTILITY(U,$J,358.3,19543,1,4,0)
+20 ;;=4^I69.221
+21 ;;^UTILITY(U,$J,358.3,19543,2)
+22 ;;=^5007460
+23 ;;^UTILITY(U,$J,358.3,19544,0)
+24 ;;=I69.392^^67^877^29
+25 ;;^UTILITY(U,$J,358.3,19544,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,19544,1,3,0)
+28 ;;=3^Facial weakness following cerebral infarction
+29 ;;^UTILITY(U,$J,358.3,19544,1,4,0)
+30 ;;=4^I69.392
+31 ;;^UTILITY(U,$J,358.3,19544,2)
+32 ;;=^5007517
+33 ;;^UTILITY(U,$J,358.3,19545,0)
+34 ;;=I69.192^^67^877^30
+35 ;;^UTILITY(U,$J,358.3,19545,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,19545,1,3,0)
+38 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
+39 ;;^UTILITY(U,$J,358.3,19545,1,4,0)
+40 ;;=4^I69.192
+41 ;;^UTILITY(U,$J,358.3,19545,2)
+42 ;;=^5007454
+43 ;;^UTILITY(U,$J,358.3,19546,0)
+44 ;;=I69.292^^67^877^32
+45 ;;^UTILITY(U,$J,358.3,19546,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,19546,1,3,0)
+48 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
+49 ;;^UTILITY(U,$J,358.3,19546,1,4,0)
+50 ;;=4^I69.292
+51 ;;^UTILITY(U,$J,358.3,19546,2)
+52 ;;=^5007486
+53 ;;^UTILITY(U,$J,358.3,19547,0)
+54 ;;=I69.092^^67^877^31
+55 ;;^UTILITY(U,$J,358.3,19547,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,19547,1,3,0)
+58 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
+59 ;;^UTILITY(U,$J,358.3,19547,1,4,0)
+60 ;;=4^I69.092
+61 ;;^UTILITY(U,$J,358.3,19547,2)
+62 ;;=^5007422
+63 ;;^UTILITY(U,$J,358.3,19548,0)
+64 ;;=I69.892^^67^877^33
+65 ;;^UTILITY(U,$J,358.3,19548,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,19548,1,3,0)
+68 ;;=3^Facial weakness following other cerebrovascular disease
+69 ;;^UTILITY(U,$J,358.3,19548,1,4,0)
+70 ;;=4^I69.892
+71 ;;^UTILITY(U,$J,358.3,19548,2)
+72 ;;=^5007548
+73 ;;^UTILITY(U,$J,358.3,19549,0)
+74 ;;=I69.351^^67^877^36
+75 ;;^UTILITY(U,$J,358.3,19549,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,19549,1,3,0)
+78 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
+79 ;;^UTILITY(U,$J,358.3,19549,1,4,0)
+80 ;;=4^I69.351
+81 ;;^UTILITY(U,$J,358.3,19549,2)
+82 ;;=^5007504
+83 ;;^UTILITY(U,$J,358.3,19550,0)
+84 ;;=I69.352^^67^877^35
+85 ;;^UTILITY(U,$J,358.3,19550,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,19550,1,3,0)
+88 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
+89 ;;^UTILITY(U,$J,358.3,19550,1,4,0)
+90 ;;=4^I69.352
+91 ;;^UTILITY(U,$J,358.3,19550,2)
+92 ;;=^5007505
+93 ;;^UTILITY(U,$J,358.3,19551,0)
+94 ;;=I69.353^^67^877^37
+95 ;;^UTILITY(U,$J,358.3,19551,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,19551,1,3,0)
+98 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
+99 ;;^UTILITY(U,$J,358.3,19551,1,4,0)
+100 ;;=4^I69.353
+101 ;;^UTILITY(U,$J,358.3,19551,2)
+102 ;;=^5007506
+103 ;;^UTILITY(U,$J,358.3,19552,0)
+104 ;;=I69.354^^67^877^38
+105 ;;^UTILITY(U,$J,358.3,19552,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,19552,1,3,0)
+108 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
+109 ;;^UTILITY(U,$J,358.3,19552,1,4,0)
+110 ;;=4^I69.354
+111 ;;^UTILITY(U,$J,358.3,19552,2)
+112 ;;=^5007507
+113 ;;^UTILITY(U,$J,358.3,19553,0)
+114 ;;=I69.151^^67^877^41
